Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
December 06, 2022 01:00 ET
|
Kinarus Therapeutic Holding AG
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and Kinarus report...
Global Age-related Macular Degeneration Market Report 2022 to 2030: High R&D Investments, Product Launches, Rising Age-Related Macular Degeneration (AMD) Prevalence are Driving Growth
December 02, 2022 06:23 ET
|
Research and Markets
Dublin, Dec. 02, 2022 (GLOBE NEWSWIRE) -- The "Age-related Macular Degeneration Market Size, Share & Trends Analysis Report by Product (Eylea, Lucentis, Beovu), by Disease Type (Wet AMD, Dry...
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
December 01, 2022 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced that the scientific rationale, supporting...
Macular Degeneration (AMD) and Other Retinal Diseases Drugs market is projected to grow at a CAGR of 10.74% by 2032: Visiongain Reports Ltd
November 28, 2022 12:08 ET
|
Visiongain Reports Ltd
Visiongain has published a new report entitled Macular Degeneration (AMD) and Other Retinal Diseases Drugs 2022-2032. It includes profiles of Macular Degeneration (AMD) and Other Retinal Diseases...
Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
November 28, 2022 07:30 ET
|
Ocugen
MALVERN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
November 22, 2022 01:00 ET
|
Kinarus Therapeutic Holding AG
Method-of-use-patent covers KIN001 in ophthalmic diseasesFurther strengthens already granted KIN001 US composition of matter patent Basel, Switzerland, 22 November 2022. Kinarus Therapeutics...
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
November 16, 2022 01:00 ET
|
Kinarus Therapeutic Holding AG
Kinarus to explore partnerships in China to fund Phase 2 clinical trials of KIN001 and explore further business opportunitiesMultiple opportunities for KIN001 in indications with high unmet need are...
Kinarus Therapeutics Provides Strategic Update
November 04, 2022 02:00 ET
|
Kinarus Therapeutic Holding AG
Exploring financial and strategic options to fund Phase 2 trials of KIN001 in wet age-related macular degeneration and idiopathic pulmonary fibrosisKINFAST phase 2 clinical trial of KIN001 in mild to...
Macular Degeneration Treatment Market, 2022: Industry surge ahead at a CAGR of 7.4% to reach US$ 18.8 Bn in 2032 - Persistence Market Research
November 03, 2022 09:30 ET
|
Persistence Market Research
New York , Nov. 03, 2022 (GLOBE NEWSWIRE) -- The global macular degeneration treatment market recorded a CAGR of 6.2% in the last 9 years from 2012 to 2021 and reached a market value of around US$...
KYS Vision Reports Clinical Trial Results of Its Remote Physiologic Monitoring System for Patients With Chronic Retinal Conditions
October 31, 2022 08:00 ET
|
KYS Vision, Inc.
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- KYS Vision, Inc., an eye care digital health company, today announced clinical trial results of its Macustat® macular function scan for the remote...